original ) (raw )
2016
visibility
…
description
7 pages
link
1 file
1 Promising clinical efficacy of the combination streptomycin – rifampin for the treatment of Buruli ulcer (Mycobacterium ulcerans disease) Running title: streptomycin + rifampin for treatment of Buruli ulcer
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.
Promising Clinical Efficacy of Streptomycin-Rifampin Combination for Treatment of Buruli Ulcer (Mycobacterium ulcerans Disease
Christian Johnson
Antimicrobial Agents and Chemotherapy, 2007
View PDFchevron_right
Efficacy of the Combination Rifampin-Streptomycin in Preventing Growth of Mycobacterium ulcerans in Early Lesions of Buruli Ulcer in Humans
Kingsley boateng
Antimicrobial Agents and Chemotherapy, 2005
View PDFchevron_right
Clinical and Bacteriological Efficacy of Rifampin-Streptomycin Combination for Two Weeks followed by Rifampin and Clarithromycin for Six Weeks for Treatment of Mycobacterium ulcerans Disease
Richard O Phillips
Antimicrobial Agents and Chemotherapy, 2014
View PDFchevron_right
Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease
Fred Sarfo
Antimicrobial agents …, 2010
View PDFchevron_right
Impacts of Dosing Frequency of the Combination Rifampin-Streptomycin on Its Bactericidal and Sterilizing Activities against Mycobacterium ulcerans in Mice
Murad Ibrahim
Antimicrobial Agents and Chemotherapy, 2009
View PDFchevron_right
High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease
Jacques Grosset
Antimicrobial Agents and Chemotherapy, 2018
View PDFchevron_right
Outcome of Streptomycin-Rifampicin treatment of Buruli Ulcer in two Ghanaian districts
Edwin Afari
Pan African Medical Journal, 2016
View PDFchevron_right
Oral Treatment for Mycobacterium ulcerans Infection: Results From a Pilot Study in Benin
Gerd Pluschke
Clinical Infectious Diseases, 2011
View PDFchevron_right
Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer
Rokeya Tasneen
PLOS Neglected Tropical Diseases, 2018
View PDFchevron_right
Activities of Rifampin, Rifapentine and Clarithromycin Alone and in Combination against Mycobacterium ulcerans Disease in Mice
Jacques Grosset
PLoS Neglected Tropical Diseases, 2011
View PDFchevron_right
Bacteriological and immunological studies towards effective control of "Mycobacterium ulcerans" disease (Buruli ulcer)
Dorothy Yeboah-Manu
2006
View PDFchevron_right
Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial
Samuel Mireku
The Lancet
View PDFchevron_right
Key words Buruli Ulcer Streptomycin Mycobacterium Ulcerans Rifampin
Annick Chauty